Skip to main content
Log in

Novel Approaches for Visualizing and Analyzing Dose-Timing Data from Electronic Drug Monitors, or “How the ‘Broken Window’ Theory Pertains to ART Adherence”

  • Original Paper
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

Adherence to antiretroviral medications is usually expressed in terms of the proportion of doses taken. However, the timing of doses taken may also be an important dimension to overall adherence. Little is known about whether patients who mistime doses are also more likely to skip doses. Using data from the completed Adherence for Life randomized controlled trial, we created visual and statistical models to capture and analyze dose timing data collected longitudinally with electronic drug monitors (EDM). From scatter plots depicting dose time versus calendar date, we identified dominant patterns of dose taking and calculated key features [slope of line over calendar date; residual mean standard error (RMSE)]. Each was assessed for its ability to categorize subjects with ‘sub-optimal’ (<95 % of doses taken) using area under the receiver operating characteristic (AROC) curve analysis. Sixty eight subjects contributed EDM data, with ~300 to 400 observations/subject. While regression line slopes did not predict ‘sub-optimal’ adherence (AROC 0.51, 95 % CI 0.26–0.75), the variability in dose timing (RMSE) was strongly predictive (AROC 0.79, 95 % CI 0.62–0.97). Compared with the lowest quartile of RMSE (minimal dose time variability), each successive quartile roughly doubled the odds of ‘sub-optimal’ adherence (OR 2.1, 95 % CI 1.3–3.4). Patterns of dose timing and mistiming are strongly related to overall adherence behavior. Notably, individuals who skip doses are more likely to mistime doses, with the degree of risk positively correlated with the extent of dose timing variability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968–77.

    Article  CAS  PubMed  Google Scholar 

  2. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. Aids. 2001;15(16):2109–17.

    Article  CAS  PubMed  Google Scholar 

  3. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS. 2002;16(12):599–608.

    Article  PubMed  Google Scholar 

  4. Wilson IB, Tchetgen E, Spiegelman D. Patterns of adherence with antiretroviral medications: an examination of between-medication differences. J Acquir Immune Defic Syndr. 2001;28(3):259–63.

    Article  CAS  PubMed  Google Scholar 

  5. Knafl GJ, Bova CA, Fennie KP, O’Malley JP, Dieckhaus KD, Williams AB. An analysis of electronically monitored adherence to antiretroviral medications. AIDS Behav. 2010;14(4):755–68.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Knafl GJ, Fennie KP, Bova C, Dieckhaus K, Williams AB. Electronic monitoring device event modelling on an individual-subject basis using adaptive Poisson regression. Stat Med. 2004;23(5):783–801.

    Article  PubMed  Google Scholar 

  7. Ferguson NM, Donnelly CA, Hooper J, Ghani AC, Fraser C, Bartley LM, et al. Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J R Soc Interface. 2005;2(4):349–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Wilson JQ, Kelling GL. Broken Windows: the police and neighborhood safety. Atlantic 1982.

  9. Bachman Desilva M, Gifford AL, Keyi X, Li Z, Feng C, Brooks M, et al. Feasibility and acceptability of a real-time adherence device among HIV-positive IDU patients in China. AIDS Res Treat 2013;2013:957862.

  10. Haberer JE, Robbins GK, Ybarra M, Monk A, Ragland K, Weiser SD, et al. Real-time electronic adherence monitoring is feasible, comparable to unannounced pill counts, and acceptable. AIDS Behav. 2012;16(2):375–82.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Haberer JE, Kiwanuka J, Nansera D, Muzoora C, Hunt PW, So J, et al. Realtime adherence monitoring of antiretroviral therapy among hiv-infected adults and children in rural uganda. Aids. 2013;27(13):2166–8.

    Article  PubMed  Google Scholar 

  12. Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Sabin LL, Desilva MB, Hamer DH, Keyi X, Yue Y, Wen F, et al. Barriers to adherence to antiretroviral medications among patients living with HIV in southern China: a qualitative study. AIDS Care. 2008;20(10):1242–50.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Sabin LL, DeSilva MB, Hamer DH, Xu K, Zhang J, Li T, et al. Using electronic drug monitor feedback to improve adherence to antiretroviral therapy among HIV-positive patients in China. AIDS Behav. 2010;14(3):580–9.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. Aids. 2006;20(1):41–8.

    Article  PubMed  Google Scholar 

  16. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146(8):564–73.

    Article  PubMed  Google Scholar 

  17. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.

    Article  CAS  PubMed  Google Scholar 

  18. Mocroft A, Horban A, Clumeck N, Stellbrink HJ, Monforte ADA, Zilmer K, et al. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naive patients starting cART after January 1, 2000. HIV Clin Trials. 2006;7(6):271–84.

    Article  CAS  PubMed  Google Scholar 

  19. Weiser SD, Guzman D, Riley ED, Clark R, Bangsberg DR. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin Trials. 2004;5(5):278–87.

    Article  PubMed  Google Scholar 

  20. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retrovir. 2011;27(1):5–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Phanuphak P, Sirivichayakul S, Jiamsakul A, Sungkanuparph S, Kumarasamy N, Lee MP, et al. Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia. J Acquir Immune Defic Syndr. 2014;66(1):74–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Mantovani NP, Azevedo RG, Rabelato JT, Sanabani S, Diaz RS, Komninakis SV. Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in Sao Paulo, Brazil. J Clin Microbiol. 2012;50(6):2122–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Sherr L, Lampe F, Norwood S, Leake Date H, Harding R, Johnson M, et al. Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care. 2008;20(4):442–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We wish to thank Ka Lai Poon for her assistance in generating the library of subject-by-subject scatter plots for this analysis. The AFL study was supported by a cooperative agreement (GHS-A-00-03-00030-00) between Boston University and the Office of Health and Nutrition of the United States Agency for International Development (USAID), with additional support from the World Health Organization (WHO) and CDC-GAP/China. Dr. Gill’s work was supported by NIH/NIAID K23 AI 62208. This study was supported by a cooperative agreement (GHS-A-00-03-00030-00) between Boston University and the Office of Health and Nutrition of the United States Agency for International Development (USAID), with additional support from the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention.

Conflict of interest

All authors declare no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christopher J. Gill.

Electronic supplementary material

Below is the link to the electronic supplementary material.

10461_2015_1065_MOESM1_ESM.docx

Supplementary material 1 (DOCX 2193 kb). A. SAS codes used to generate the uni- and bi-modal scatter plots. B. Individual subject uni-modal scatter plots. C. Individual subject bi-modal scatter plots

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gill, C.J., DeSilva, M.B., Hamer, D.H. et al. Novel Approaches for Visualizing and Analyzing Dose-Timing Data from Electronic Drug Monitors, or “How the ‘Broken Window’ Theory Pertains to ART Adherence”. AIDS Behav 19, 2057–2068 (2015). https://doi.org/10.1007/s10461-015-1065-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-015-1065-3

Keywords

Navigation